3 recruiting, 2 completed. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 2 | 2 | Recruiting 2 |
Follow Cue Biopharma: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs CUE-101, Pembrolizumab - Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | Yale University | 30 | 2026-05-07 | 2026-07-30 |
| CUE-102 in Recurrent Glioblastoma CUE-102 - Recurrent Glioblastoma, Glioblastoma | Phase 1 | Recruiting | David Reardon, MD | 18 | 2025-07-30 | 2026-03-05 |
| A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers CUE-102 - Colorectal Cancer, Gastric Cancer | Phase 1 | Completed | Cue Biopharma | 42 | 2022-06-14 | 2026-01-22 |
| Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Positive Patients With Locally Advanced, HPV16-Positive Oropharyngeal Squamous-Cell Carcinoma CUE-101 - Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | Washington University School of Medicine | 30 | 2021-12-06 | 2026-07-20 |
| A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma CUE-101, KEYTRUDA®, Pembrolizumab - Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 1 | Completed | Cue Biopharma | 80 | 2019-07-30 | 2026-01-22 |
Squamous Cell Carcinoma of Head and Neck (2) · Colorectal Neoplasms (1) · Glioblastoma (1) · Glioma (1) · Head and Neck Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1) · Wilms Tumor (1)
pembrolizumab (2)
United States (5)
Matteo Levisetti, MD (2) · David Reardon, MD (1) · Jesse Zaretsky, M.D. (1) · Sara Pai, MD (1)